AzTrials
AzTrials

Rheumatoid ArthritisPhase 2OSKIRA-Asia-1NCT01569074

Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis

A Phase 2 study testing Fostamatinib in people with Rheumatoid Arthritis, run by AstraZeneca at 34 sites in 6 countries.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The purpose of the study is to evaluate the effectiveness of four dosing regimens of fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking methotrexate but not responding. The study will last for 12 weeks. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Rheumatoid Arthritis
What is being tested?
Fostamatinib
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
163 participants
Where
34 sitesin 6 countries
Study dates
Apr 2012to Jul 2013
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male or female aged 18 and over
  • Active rheumatoid arthritis (RA) diagnosed after the age of 16
  • 6 or more swollen joints and 6 or more tender/painful joints from certain joints in the hands, wrists, arms and knees
  • At least one of: positive result for rheumatoid factor test, either in the past or currently (blood test); x-ray showing bone erosion within the last 12 months; presence of certain antibodies in the blood (blood test)
  • Currently taking methotrexate for at least 4 months (and on a stable dose for at least 6 weeks)

Who cannot join

  • Females who are pregnant or breast feeding
  • Certain inflammatory conditions (other than rheumatoid arthritis), connective tissue diseases or chronic pain disorders.
  • Previously taken, but not responded to, certain biological treatments for rheumatoid arthritis
  • High blood pressure that is not controlled by medication
  • Low levels of neutrophils in the blood (blood test).

Trial locations and contacts

34 sites in 6 countries.

34 sites in 6 countries

Japan20 sites
  • Research Site

    Fukuoka, Fukuoka

  • Research Site

    Hamamatsu, Shizuoka

  • Research Site

    Isahaya, Nagasaki

  • Research Site

    Kasama-shi, Ibaraki

  • Research Site

    Kato-shi, Hyōgo

  • Research Site

    Kitakyushu-shi, Fukuoka

  • Research Site

    Kumamoto, Kumamoto

  • Research Site

    Kurume, Fukuoka

  • Research Site

    Matsue, Shimane

  • Research Site

    Matsuyama, Ehime

  • Research Site

    Nagasaki, Nagasaki

  • Research Site

    Okayama, Okayama-ken

  • Research Site

    Omura-shi, Nagasaki

  • Research Site

    Sapporo, Hokkaido

  • Research Site

    Sasebo-shi, Nagasaki

  • Research Site

    Sendai, Miyagi

  • Research Site

    Shibata, Niigata

  • Research Site

    Shinjuku, Tokyo

  • Research Site

    tabashi City, Tokyo

  • Research Site

    Tomigusuku-shi, Okinawa

Other trials in Japan

South Korea4 sites
  • Research Site

    Anyang-si, Gyeonggi-do

  • Research Site

    Gwangju

  • Research Site

    Incheon

  • Research Site

    Seoul

Other trials in South Korea

Taiwan4 sites
  • Research Site

    Chiayi City

  • Research Site

    Kaohsiung City

  • Research Site

    Taichung

  • Research Site

    Taipei

Other trials in Taiwan

Hong Kong2 sites
  • Research Site

    Hong Kong

  • Research Site

    New Territories, HK

Other trials in Hong Kong

Thailand2 sites
  • Research Site

    Bangkok

  • Research Site

    Singapore

Other trials in Thailand

Vietnam2 sites
  • Research Site

    Hanoi

  • Research Site

    Ho Chi Minh City

Other trials in Vietnam

About this study

Official title: (OSKIRA-Asia-1): A Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose Ranging Study in Asia Evaluating Efficacy and Safety of Fostamatinib in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate Therapy

The purpose of the study is to evaluate the effectiveness of four dosing regimens of fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking methotrexate but not responding. The study will last for 12 weeks.

Read the detailed description

(OSKIRA-Asia-1): A Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose Ranging Study in Asia Evaluating Efficacy and Safety of Fostamatinib in Patients with Active Rheumatoid Arthritis who are Inadequate Responders to Methotrexate Therapy

Being tested
Fostamatinib, Placebo
Keywords
Rheumatoid Arthritis
Medical subject headings
Arthritis, Rheumatoid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • FostamatinibDrug

    Fostamatinib 100mg twice daily for 12 weeks

  • FostamatinibDrug

    Fostamatinib 100mg twice daily for 4 weeks, followed by150mg once daily up to Week 12

  • FostamatinibDrug

    Fostamatinib 75mg twice daily for 12 weeks

  • FostamatinibDrug

    Fostamatinib 50mg twice daily for 12 weeks

  • PlaceboDrug

    Placebo twice daily for 12 weeks

Study groups in NCT01569074
Study groupRoleWhat they receive
Dosing A regimenExperimentalOral treatment
Receives: Drug: Fostamatinib
Dosing B regimenExperimentalOral treatment
Receives: Drug: Fostamatinib
Dosing C regimenExperimentalOral treatment
Receives: Drug: Fostamatinib
Dosign D regimenExperimentalOral treatment
Receives: Drug: Fostamatinib
Dosing E regimenPlacebo comparatorOral treatment
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Proportion of Patients Achieving ACR20 at Week 12, Comparison Between Fostamatinib and Placebo

    ACR20: American College of Rheumatology 20% response criteria, based on count of swollen and tender joints (out of 28 joints), blood test measures of inflammation (such as C-Reactive Protein) and the physician and patient's own assessments of disease activity, pain and physical function. BID = twice daily, DMARD = disease-modifying anti-rheumatic drug, PO = orally, QD = once a day.

    Measured: 12 weeks

Secondary outcomes (9)
  1. Proportion of Patients Achieving ACR20 at Week 1, Comparison Between Fostamatinib and Placebo

    ACR20: American College of Rheumatology 20% response criteria, based on count of swollen and tender joints (out of 28 joints), blood test measures of inflammation (such as C-Reactive Protein) and the physician and patient's own assessments of disease activity, pain and physical function. BID = twice daily, DMARD = disease-modifying anti-rheumatic drug, PO = orally.

    Measured: 1 week

  2. Proportion of Patients Achieving ACR50 at Week 12, Comparison Between Fostamatinib and Placebo

    ACR50: American College of Rheumatology 50% response criteria, based on count of swollen and tender joints (out of 28 joints), blood test measures of inflammation (such as C-Reactive Protein) and the physician and patient's own assessments of disease activity, pain and physical function, BID = twice daily, DMARD = disease-modifying anti-rheumatic drug, PO = orally, QD = once a day.

    Measured: 12 weeks

  3. Proportion of Patients Achieving ACR70 at Week 12, Comparison Between Fostamatinib and Placebo

    ACR70: American College of Rheumatology 70% response criteria, based on count of swollen and tender joints (out of 28 joints), blood test measures of inflammation (such as C-Reactive Protein) and the physician and patient's own assessments of disease activity, pain and physical function. BID = twice daily, DMARD = disease-modifying anti-rheumatic drug, PO = orally, QD = once a day.

    Measured: 12 weeks

  4. ACRn - Comparison Between Fostamatinib and Placebo at Week 12

    ACRn: American College of Rheumatology index of RA improvement, based on smallest percentage improvement in the count of swollen joints (out of 28 joints), count of tender joints (out of 28 joints), or in blood test measures of inflammation (such as C-Reactive Protein) or the physician or patient's own assessments of disease activity, pain and physical function. Scores are reported as a percentage improvement on a scale of -100 to +100, with larger values representing a better clinical outcome. Mean refers to change at Week 12. BID = twice daily, DMARD = disease-modifying anti-rheumatic drug, PO = orally, QD = once a day.

    Measured: Baseline and 12 weeks

  5. Proportion of Patients Achieving DAS28-CRP<=3.2 at Week 12, Comparison Between Fostamatinib and Placebo

    DAS28-CRP: Disease Activity Score based on a count of swollen and tender joints (out of 28 joints), blood test measures of inflammation (CRP) and the patient's own assessment. Scores can take any positive value with a lower value indicating a better clinical condition. DAS28-CRP score of <=3.2 indicates low disease activity. BID = twice daily, CRP = C-reactive protein, , DMARD = disease modifying anti-rheumatic drug, OR = odds ratio, PO = orally, QD = once daily.

    Measured: 12 weeks

  6. Proportion of Patients With DAS28-CRP EULAR Response at Week 12, Comparison Between Fostamatinib and Placebo

    Change from baseline in DAS28-CRP at Week 12 was derived and categorised using the European League Against Rheumatism (EULAR) response criteria. BID = twice a day, DMARD = disease-modifying anti-rheumatic drug, OR = odds ratio, PO = orally, QD = once a day.

    Measured: 12 weeks

  7. Proportion of Patients With HAQ-DI Response at Week 12, Comparison Between Fostamatinib and Placebo

    HAQ-DI: Health Assessment Questionnaire - Disability Index, a measure of physical function. The HAQ-DI score is calculated by summing scores from 8 sub-categories (ie, scores for patient ability in dressing and grooming, rising, eating, walking, hygiene, reach, grip and common daily activities) and dividing by the number of categories completed. The HAQ-DI score takes values between 0 and 3, with higher score indicating greater disability. HAQ-DI response is a reduction from baseline in HAQ-DI greater than or equal to the minimally important difference (0.22). BID = twice daily, DMARD = disease-modifying anti-rheumatic drug, OR = odds ratio, PO = orally, QD = once a day.

    Measured: 12 weeks

  8. SF-36 - Comparison of the Change in PCS From Baseline Between Fostamatinib and Placebo at Week 12

    SF-36 = 36-item Short Form Health Survey, as a measure of health related quality of life. Scores for 8 sub-domains (Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Function, Role-Emotional and Mental Health) are derived and normalised to a scale of 0 to 100. The physical and mental component scores (PCS and MCS) are derived by multiplying each of these 8 scores by a constant, summing them and standardising against a population with mean of 50, standard deviation of 10. A higher score represents better quality of life. Mean changes from baseline are presented as increases from baseline (defined as post-baseline minus baseline); larger changes indicate a better clinical condition. Mean refers to change in scores at Week 12. ANCOVA = analysis of covariance, BID = twice daily, DMARD = disease-modifying anti-rheumatic drug, PO = orally, QD = once a day.

    Measured: Baseline and 12 weeks

  9. SF-36 - Comparison of the Change in MCS From Baseline Between Fostamatinib and Placebo at Week 12

    SF-36 = 36-item Short Form Health Survey, as a measure of health related quality of life. Scores for 8 sub-domains (Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Function, Role-Emotional and Mental Health) are derived and normalised to a scale of 0 to 100. The physical and mental component scores (PCS and MCS) are derived by multiplying each of these 8 scores by a constant, summing them and standardising against a population with mean of 50, standard deviation of 10. A higher score represents better quality of life. Mean changes from baseline are presented as increases from baseline (defined as post-baseline minus baseline); larger changes indicate a better clinical condition. Mean refers to change in scores at Week 12. ANCOVA = analysis of covariance, BID = twice daily, DMARD = disease-modifying anti-rheumatic drug, PO = orally, QD = once a day.

    Measured: Baseline and 12 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Apr 2012 (estimated)
  2. Study startApr 2012
  3. Primary completionJul 2013
  4. Study completionJul 2013

Why it stopped: AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to Rigel Pharmaceuticals.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
163 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01569074
Sponsor's protocol ID
D4300C00008
Acronym
OSKIRA-Asia-1
Status last verified
Feb 2014
First submitted
30 Mar 2012
Last updated
7 Apr 2014
Data monitoring committee
Yes

Publications

  • Tanaka Y, Millson D, Iwata S, Nakayamada S. Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study. Rheumatology (Oxford). 2021 Jun 18;60(6):2884-2895. doi: 10.1093/rheumatology/keaa732.

    PubMed 33254235

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Fostamatinib in people with Rheumatoid Arthritis, run by AstraZeneca at 34 sites in 6 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 7 Apr 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 34 sites in Japan, South Korea, Taiwan, Hong Kong, Thailand and 1 more country. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 7 Apr 2014). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Proportion of Patients Achieving ACR20 at Week 12, Comparison Between Fostamatinib and Placebo (time frame: 12 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01569074, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Apr 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in